<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00398866</url>
  </required_header>
  <id_info>
    <org_study_id>K23AR050607</org_study_id>
    <secondary_id>K23AR050607</secondary_id>
    <secondary_id>5K23AR050607-04</secondary_id>
    <secondary_id>26043</secondary_id>
    <nct_id>NCT00398866</nct_id>
  </id_info>
  <brief_title>A Study of Hyaluronan for the Treatment of Osteoarthritis in the Thumb</brief_title>
  <official_title>A Study of Hyaluronan (Synvisc) for the Treatment of Osteoarthritis in the Thumb: Randomized Control Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospital for Special Surgery, New York</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>Genzyme, a Sanofi Company</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Hospital for Special Surgery, New York</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Hyaluronan is a man-made preparation of a protein complex that occurs naturally in joints and
      that is often low in people with osteoarthritis. Although hyaluronan has been used in
      millions of people with knee osteoarthritis, it is not yet FDA approved for use in the thumb.
      The purpose of this study is to determine the safety and effectiveness of hyaluronan in
      relieving arthritis symptoms at the base of the thumb and to compare it to corticosteroids
      and local anesthetic.

      The principle hypothesis is that treating osteoarthritis at the carpometacarpophalangeal
      (CMC) joint with injectable hyaluronan will results in greater pain relief, higher patient
      satisfaction, and better functional outcomes than treating with placebo injections (local
      anesthetic) or with corticosteroid injections. Treating CMC osteoarthritis with
      corticosteroid injections will result in greater pain relief, higher patient satisfaction,
      and better functional outcomes than treating with placebo injections. Patients with worse
      pre-treatment function will have less improvement and worse post-treatment results after
      administration of corticosteroid or hyaluronan.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Osteoarthritis involves a wearing down of the cartilage within a joint. It can affect any
      joint in the body, but it most commonly affects joints in the hands, hips, knees, and spine.
      Over the last few years, a new medicine called hyaluronan has been used for treating
      osteoarthritis. Hyaluronan is a man-made preparation of a protein complex that occurs
      naturally in joints and that is often low in people with osteoarthritis. Although hyaluronan
      has been used in millions of people with knee osteoarthritis, it is not yet FDA approved for
      use in the thumb. The purpose of this study is to determine the safety and effectiveness of
      hyaluronan in relieving arthritis symptoms at the base of the thumb and to compare it to
      corticosteroids and local anesthetic. Specifically, the study will evaluate pain relief,
      patient satisfaction, and functional outcomes among participants.

      Participation in this study will last 26 weeks. Screening will include a questionnaire and an
      x-ray of the affected thumb. Eligible participants will then be randomly assigned to one of
      three treatments: two hyaluronan injections, one corticosteroid injection plus one local
      anesthetic injection, or two local anesthetic injections. Participants will receive the
      injections at the base of their thumb, and the first injection will be followed by the second
      injection a week later. There will be five study visits that will occur at baseline and Weeks
      2, 4, 12, and 26. All study visits will include questionnaires, and except for the Week 2
      study visit, they will also include an examination and evaluation of the affected thumb.
      Photographs of the thumb will be taken at baseline. The injections will occur at baseline and
      Week 2. At Weeks 8 and 20, questionnaires will be mailed to participants for them to
      complete. Upon completing the study, participants will have the option of receiving continued
      treatment with another round of hyaluronic injections.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2006</start_date>
  <completion_date type="Actual">March 2013</completion_date>
  <primary_completion_date type="Actual">March 2013</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pain Visual Analogue Scale (VAS)</measure>
    <time_frame>Baseline, 26 Weeks</time_frame>
    <description>Pain intensity measured on a Visual Analog Scale with scores ranging from 0 to 100, with 100 = severe pain.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Disabilities of the Arm, Shoulder and Hand (DASH) Questionnaire</measure>
    <time_frame>Baseline, 26 Weeks</time_frame>
    <description>Disabilities of the Arm, Shoulder and Hand (DASH) Questionnaire measures degree of disability on a scale of 0 to 100, with a higher score indicating greater disability.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">200</enrollment>
  <condition>Osteoarthritis</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Bupivicaine (local anesthetic)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Corticosteroid (trimcinolone (Kenalog) 40 mg)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Synvisc</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Synvisc (Hylan G-F20; hyaluronan injection)</intervention_name>
    <description>1 ml of hyaluronan (Synvisc) injected once a week for 2 consecutive weeks</description>
    <arm_group_label>3</arm_group_label>
    <other_name>Synvisc, Hyalgan, Hyaluronic Acid</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bupivicaine (local anesthesia injection)</intervention_name>
    <description>1 ml of bupivicaine 0.5% injected once a week for 2 weeks</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Kenalog (triamcinolone; corticosteroid injection)</intervention_name>
    <description>1 ml (40mg) of triamcinolone (Kenalog) injected the first week, followed by a placebo injection of 1 ml 0.5% bupivacaine the second week; Kenalog is a non-suspension steroid preparation and is less likely to cause post-injection flares than a suspension preparation</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Presence of osteophytes or sclerosis at the carpometacarpal (CMC) joint

          -  Complaint of unacceptable pain despite modification of activity and a therapeutic dose
             of nonsteroidal anti-inflammatory drugs (NSAIDS), if tolerated

          -  If bilateral disease, only the most severely involved hand (as defined by the visual
             analog scale [VAS] for pain) will be entered in the study

          -  Able to follow instructions and complete questionnaires

          -  Failed conservative therapy with NSAIDS or COX-2 inhibitors

          -  Unable to tolerate COX-2 inhibitors

        Exclusion Criteria:

          -  Previous traumatic dislocation, ligament tear, or fracture of the thumb in the
             affected hand

          -  Previous hand surgery on the affected hand

          -  Known hand comorbidities (e.g., active carpal tunnel syndrome, de Quervains
             tenosynovitis, etc.)

          -  Systemic rheumatic disease

          -  Bleeding diatheses or anti-coagulation

          -  Allergies to steroids, chicken products, bupivicaine, or adhesive (e.g., double-sided
             tape)

          -  Current use of oral or intravenous steroids

          -  Active systemic malignancies

          -  Hyaluronan injection in the target CMC joint in the last 6 months

          -  Steroid or hyaluronan injection in any other joint in the last 6 months

          -  Insulin dependent diabetes mellitus (IDDM)

          -  Active infection

          -  Pain in the index joint that is more than 40 out of 100 on a VAS Pain scale

          -  End Stage CMC osteoarthritis, equivalent to bone on bone, Kellgren and Lawrence Stage
             IV

          -  Grade 3 or 4 Eaton and Litter (E+L) Classification

          -  E+L 3: Advanced joint distraction, subchondral cysts, and sclerosis

          -  E+L 4: Involvement of several joint surfaces
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>45 Years</minimum_age>
    <maximum_age>95 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lisa A. Mandl, MD, MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital for Special Surgery, New York</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hospital for Special Surgery</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 10, 2006</study_first_submitted>
  <study_first_submitted_qc>November 10, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 14, 2006</study_first_posted>
  <results_first_submitted>April 4, 2017</results_first_submitted>
  <results_first_submitted_qc>July 5, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">July 7, 2017</results_first_posted>
  <last_update_submitted>July 5, 2017</last_update_submitted>
  <last_update_submitted_qc>July 5, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 7, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hyaluronan</keyword>
  <keyword>Carpometacarpal</keyword>
  <keyword>Outcomes</keyword>
  <keyword>Carpometacarpal Joints</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoarthritis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bupivacaine</mesh_term>
    <mesh_term>Triamcinolone hexacetonide</mesh_term>
    <mesh_term>Triamcinolone</mesh_term>
    <mesh_term>Triamcinolone Acetonide</mesh_term>
    <mesh_term>Hyaluronic Acid</mesh_term>
    <mesh_term>Triamcinolone diacetate</mesh_term>
    <mesh_term>Hylan</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Patients were recruited from the practices of Hospital for Special Surgery (HSS) physicians or were or self-referred. Study information was posted on the HSS website, clinicaltrials.gov, Craig's List and local newspapers. Recruitment occurred between 05/25/2007 and 07/15/2009.</recruitment_details>
      <pre_assignment_details>396 subjects screened 169 did not meet eligibility criteria 27 declined injection 200 subjects randomized</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Bupivicaine</title>
          <description>Bupivicaine (local anesthetic)
Bupivicaine (local anesthesia injection): 1 ml of bupivicaine 0.5% injected once a week for 2 weeks</description>
        </group>
        <group group_id="P2">
          <title>Triamcinolone</title>
          <description>Corticosteroid (triamcinolone (Kenalog) 40 mg)
Kenalog (triamcinolone; corticosteroid injection): 1 ml (40mg) of triamcinolone (Kenalog) injected the first week, followed by a placebo injection of 1 ml 0.5% bupivacaine the second week; Kenalog is a non-suspension steroid preparation and is less likely to cause post-injection flares than a suspension preparation</description>
        </group>
        <group group_id="P3">
          <title>Hylan G-F 20</title>
          <description>Synvisc
Synvisc (Hylan G-F20; hyaluronan injection): 1 ml of hyaluronan (Synvisc) injected once a week for 2 consecutive weeks</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="66"/>
                <participants group_id="P2" count="68"/>
                <participants group_id="P3" count="66"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="52"/>
                <participants group_id="P2" count="60"/>
                <participants group_id="P3" count="58"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="8"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Unable to complete requirements of study</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Bupivicaine</title>
          <description>Bupivicaine (local anesthetic)
Bupivicaine (local anesthesia injection): 1 ml of bupivicaine 0.5% injected once a week for 2 weeks</description>
        </group>
        <group group_id="B2">
          <title>Triamcinolone</title>
          <description>Corticosteroid (trimcinolone (Kenalog) 40 mg)
Kenalog (triamcinolone; corticosteroid injection): 1 ml (40mg) of triamcinolone (Kenalog) injected the first week, followed by a placebo injection of 1 ml 0.5% bupivacaine the second week; Kenalog is a non-suspension steroid preparation and is less likely to cause post-injection flares than a suspension preparation</description>
        </group>
        <group group_id="B3">
          <title>Hylan G-F 20</title>
          <description>Synvisc
Synvisc (Hylan G-F20; hyaluronan injection): 1 ml of hyaluronan (Synvisc) injected once a week for 2 consecutive weeks</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="66"/>
            <count group_id="B2" value="68"/>
            <count group_id="B3" value="66"/>
            <count group_id="B4" value="200"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="66.3" spread="9.3"/>
                    <measurement group_id="B2" value="66.6" spread="8.4"/>
                    <measurement group_id="B3" value="67.1" spread="10.1"/>
                    <measurement group_id="B4" value="66.7" spread="9.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex/Gender, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Gender</title>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="50"/>
                    <measurement group_id="B2" value="40"/>
                    <measurement group_id="B3" value="45"/>
                    <measurement group_id="B4" value="135"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="28"/>
                    <measurement group_id="B3" value="20"/>
                    <measurement group_id="B4" value="64"/>
                  </measurement_list>
                </category>
                <category>
                  <title>No data</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Race</title>
              <category_list>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="58"/>
                    <measurement group_id="B2" value="61"/>
                    <measurement group_id="B3" value="61"/>
                    <measurement group_id="B4" value="180"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Other</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="19"/>
                  </measurement_list>
                </category>
                <category>
                  <title>No data</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Pain Visual Analogue Scale (VAS)</title>
        <description>Pain intensity measured on a Visual Analog Scale with scores ranging from 0 to 100, with 100 = severe pain.</description>
        <time_frame>Baseline, 26 Weeks</time_frame>
        <population>Patients who completed follow-up through 26 weeks</population>
        <group_list>
          <group group_id="O1">
            <title>Bupivicaine</title>
            <description>Bupivicaine (local anesthetic)
Bupivicaine (local anesthesia injection): 1 ml of bupivicaine 0.5% injected once a week for 2 weeks</description>
          </group>
          <group group_id="O2">
            <title>Triamcinolone</title>
            <description>Corticosteroid (trimcinolone (Kenalog) 40 mg)
Kenalog (triamcinolone; corticosteroid injection): 1 ml (40mg) of triamcinolone (Kenalog) injected the first week, followed by a placebo injection of 1 ml 0.5% bupivacaine the second week; Kenalog is a non-suspension steroid preparation and is less likely to cause post-injection flares than a suspension preparation</description>
          </group>
          <group group_id="O3">
            <title>Hylan G-F 20</title>
            <description>Synvisc
Synvisc (Hylan G-F20; hyaluronan injection): 1 ml of hyaluronan (Synvisc) injected once a week for 2 consecutive weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Pain Visual Analogue Scale (VAS)</title>
          <description>Pain intensity measured on a Visual Analog Scale with scores ranging from 0 to 100, with 100 = severe pain.</description>
          <population>Patients who completed follow-up through 26 weeks</population>
          <units>Units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="61"/>
                <count group_id="O2" value="65"/>
                <count group_id="O3" value="62"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Pain VAS at Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="57.1" spread="20.1"/>
                    <measurement group_id="O2" value="63.2" spread="20.2"/>
                    <measurement group_id="O3" value="60.7" spread="19.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pain VAS at 26 weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42.9" spread="26.5"/>
                    <measurement group_id="O2" value="50.1" spread="29.4"/>
                    <measurement group_id="O3" value="49.8" spread="26.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Disabilities of the Arm, Shoulder and Hand (DASH) Questionnaire</title>
        <description>Disabilities of the Arm, Shoulder and Hand (DASH) Questionnaire measures degree of disability on a scale of 0 to 100, with a higher score indicating greater disability.</description>
        <time_frame>Baseline, 26 Weeks</time_frame>
        <population>Patients who completed follow-up through 26 weeks</population>
        <group_list>
          <group group_id="O1">
            <title>Bupivicaine</title>
            <description>Bupivicaine (local anesthetic)
Bupivicaine (local anesthesia injection): 1 ml of bupivicaine 0.5% injected once a week for 2 weeks</description>
          </group>
          <group group_id="O2">
            <title>Triamcinolone</title>
            <description>Corticosteroid (triamcinolone (Kenalog) 40 mg)
Kenalog (triamcinolone; corticosteroid injection): 1 ml (40mg) of triamcinolone (Kenalog) injected the first week, followed by a placebo injection of 1 ml 0.5% bupivacaine the second week; Kenalog is a non-suspension steroid preparation and is less likely to cause post-injection flares than a suspension preparation</description>
          </group>
          <group group_id="O3">
            <title>Hylan G-F 20</title>
            <description>Synvisc
Synvisc (Hylan G-F20; hyaluronan injection): 1 ml of hyaluronan (Synvisc) injected once a week for 2 consecutive weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Disabilities of the Arm, Shoulder and Hand (DASH) Questionnaire</title>
          <description>Disabilities of the Arm, Shoulder and Hand (DASH) Questionnaire measures degree of disability on a scale of 0 to 100, with a higher score indicating greater disability.</description>
          <population>Patients who completed follow-up through 26 weeks</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="61"/>
                <count group_id="O2" value="65"/>
                <count group_id="O3" value="62"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>DASH at Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.7" spread="17.1"/>
                    <measurement group_id="O2" value="28.9" spread="17.9"/>
                    <measurement group_id="O3" value="28.8" spread="17.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dash at 26 Weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.2" spread="17.4"/>
                    <measurement group_id="O2" value="27.0" spread="18.0"/>
                    <measurement group_id="O3" value="26.1" spread="19.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Bupivicaine</title>
          <description>Bupivicaine (local anesthetic)
Bupivicaine (local anesthesia injection): 1 ml of bupivicaine 0.5% injected once a week for 2 weeks</description>
        </group>
        <group group_id="E2">
          <title>Triamcinolone</title>
          <description>Corticosteroid (triamcinolone (Kenalog) 40 mg)
Kenalog (triamcinolone; corticosteroid injection): 1 ml (40mg) of triamcinolone (Kenalog) injected the first week, followed by a placebo injection of 1 ml 0.5% bupivacaine the second week; Kenalog is a non-suspension steroid preparation and is less likely to cause post-injection flares than a suspension preparation</description>
        </group>
        <group group_id="E3">
          <title>Hylan G-F 20</title>
          <description>Synvisc
Synvisc (Hylan G-F20; hyaluronan injection): 1 ml of hyaluronan (Synvisc) injected once a week for 2 consecutive weeks</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="66"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Mitral Valve Surgery</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="66"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Emergency Cholecystecomy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="66"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Fall--hand injury</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="66"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="68"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="66"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Positive ANA Test (Previous status unknown)</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="68"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="66"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pain, Swelling, or Numbness in Hand</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="66"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="68"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="66"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Skin Atrophy or Depigmentation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="68"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Skin and Nail Abnormalities</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="68"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="66"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Lisa Mandl</name_or_title>
      <organization>Hospital for Special Surgery</organization>
      <phone>2127742754</phone>
      <email>MandlL@hss.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

